Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oncolytics Biotech Inc. (ONCY : NSDQ)

• Company Description    Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer. Number of Employees: 26

• Price / Volume Information    Yesterday's Closing Price: $1.07 Daily Weekly Monthly 20 Day Moving Average: 92,440 shares Shares Outstanding: 57.63 (millions) Market Capitalization: $61.67 (millions) Beta: 2.31 52 Week High: $3.21 52 Week Low: $1.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.74% -13.22% 12 Week -36.31% -28.42% Year To Date -23.02% -5.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 804 322 - 11 AVENUE SW - CALGARY,A0 T2R 0C5 CAN ph: 403-670-7377 fax: 403-283-0858 jpatton@oncolytics.ca http://www.oncolyticsbiotech.com

• General Corporate Information    Officers Matthew C. Coffey - President and Chief Executive Officer and Director Wayne Pisano - Chairman Kirk J. Look - Chief Financial Officer Deborah M. Brown - Director Angela Holtham - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 682310875 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/05/22 Share - Related Items Shares Outstanding: 57.63 Most Recent Split Date: 5.00 (0.11:1) Beta: 2.31 Market Capitalization: $61.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.34 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.23 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 10.00% vs. Previous Quarter: 18.18% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -66.47 12/31/21 - -61.94 09/30/21 - -70.06 ROA 03/31/22 - -53.50 12/31/21 - -50.38 09/30/21 - -56.36 Current Ratio 03/31/22 - 17.96 12/31/21 - 16.70 09/30/21 - 19.05 Quick Ratio 03/31/22 - 17.96 12/31/21 - 16.70 09/30/21 - 19.05 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.48 12/31/21 - 0.52 09/30/21 - 0.62 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©